11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold

Neurology
M GuttmanS Houle

Abstract

To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [11C]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (-12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.

Citations

Apr 11, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·S GoldsteinK Marek
Nov 11, 2006·European Journal of Nuclear Medicine and Molecular Imaging·A LokkegaardL Friberg
Feb 12, 2008·Acta Neuropathologica·Dennis W DicksonJ Eric Ahlskog
Feb 3, 2012·Journal of Neurology·Marios Politis, Paola Piccini
Feb 8, 2006·Journal of Neural Transmission·T Obata
Sep 1, 1997·Nature Medicine·O Isacson, X O Breakefield
Apr 29, 1998·Immunology and Cell Biology·K Bashir, J N Whitaker
May 21, 2003·Seminars in Nuclear Medicine·John P Seibyl
Aug 28, 2009·Cerebral Cortex·Rick C HelmichIvan Toni
Feb 24, 2001·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·J H Meyer, M Ichise
Apr 4, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·P K MorrishD J Brooks
Nov 24, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·J O RinneO Solin
Feb 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·A WinogrodzkaE C Wolters
Oct 2, 2012·EJNMMI Research·Miia PitkonenKim Bergström
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·David J Brooks
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·David J Brooks
Oct 16, 2010·Biomarkers in Medicine·Jakob NyhlénHenrik Zetterberg
Sep 15, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Daniela Di GiudaAlfonso Fasano
Feb 14, 2012·Neuro-degenerative Diseases·Anne M LandauDoris J Doudet
Dec 5, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·K MarekJ Seibyl
Dec 15, 2012·Expert Review of Neurotherapeutics·Rizwan S Akhtar, Matthew B Stern
May 10, 2012·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Nicolaas I BohnenKirk A Frey
Oct 8, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Paul K Morrish
Apr 18, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M GuttmanS J Kish
Oct 31, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Carles Gaig, Eduardo Tolosa
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A BerardelliM Vidailhet
Jan 2, 2014·Brain and Behavior·Craig F FerrisTakao Yagi
Apr 18, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Daniela BergWerner Poewe
Mar 26, 2005·Brain Research. Molecular Brain Research·Wing Lok AuA Jon Stoessl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.